Research ended
Nuvalent, Inc. (NUVL) was acquired by GSK for $124.00 a share in cash on 15 July 2026.
Our research on Nuvalent, Inc. ended on . Once a takeover closes, the shares stop trading under NUVL and there is nothing left to research. The last note, from , is below.
We keep this page so links to it still work and what we published about the stock stays on the record.
The last thesis
Nuvalent's equity story ended when GSK completed its $124-per-share cash acquisition on 15 July 2026; its drugs now sit inside GSK, and the 27 November 2026 FDA decision on neladalkib is the next test of that deal.